Integrating Physiologically Based Pharmacokinetic Modeling-Based Forward Dosimetry and in Vitro Bioassays to Improve the Risk Assessment of Organophosphate Esters on Human Health
Environmental Science & Technology · 2023-01-31 · 57 (4) · 1764-1775
DOI: 10.1021/acs.est.2c04576 ↗At a glance
Journal article in Environmental Science & Technology, published online on 2023-01-02. Written by Xiaolei Wang and 8 co-authors. Institution: State Key Laboratory of Environmental Criteria and Risk Assessment, Chinese Research Academy of Environmental Sciences, Beijing 100012, P. R. China. Major MEDLINE topics: Environmental Monitoring, Flame Retardants. Cited 25 times so far (Crossref); 74 references. Funded by: Ministry of Science and Technology of the People's Republic of China, National Natural Science Foundation of China.
Abstract (original language)
The ability to accurately assess the health risks of contaminants is limited by the shortcomings of toxicological standards. Using organophosphate esters (OPEs) as an example, this study attempted to integrate physiologically based pharmacokinetic (PBPK)-based forward dosimetry and in vitro bioassays to assess the likelihood of contaminants inducing biological effects in humans. The total exposure level of OPEs for Chinese residents was 19.5 ± 8.71 ng/kg/day with inhalation being the main exposure pathway. Then, human PBPK models were developed for individual OPEs to predict their steady-state concentrations in human tissues, and the predicted median levels in blood were close to the measurements. The reference doses (RfDs) of OPEs based on in vitro bioassays were comparable to in vivo animal-derived RfDs, demonstrating the reliability of in vitro bioassays. Therefore, the likelihood of OPEs inducing bioactivities in humans (RQin-vitro) was calculated using in vitro toxicity data and OPE levels in human tissues. The RQin-vitros of tris(2-chloroisopropyl) phosphate, tris(1,3-dichloropropyl) phosphate, and triphenyl phosphate (7.68 × 10-5-3.18 × 10-3) were comparable to the risks assessed using traditional RfDs (5.22 × 10-5-1.94 × 10-3), indicating the credibility of the method proposed in this study. This study establishes a new framework to improve the health risk assessment of contaminants without sufficient toxicity data and minimize the need for animal experimentation.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- State Key Laboratory of Environmental Criteria and Risk Assessment, Chinese Research Academy of Environmental Sciences, Beijing 100012, P. R. China.
- School of Space and Environment, Beihang University, Beijing 100191, P. R. China.
ORCID profiles: Xiaolei Wang, Xiaoli Zhao, Zhaomin Dong, Fengchang Wu
Funding
- Ministry of Science and Technology of the People's Republic of China
- National Natural Science Foundation of China
Cite
APA
Wang, X., Zhao, X., Shi, D., Dong, Z., Zhang, X., Liang, W., Liu, L., Wang, X., & Wu, F. (2023). Integrating Physiologically Based Pharmacokinetic Modeling-Based Forward Dosimetry and in Vitro Bioassays to Improve the Risk Assessment of Organophosphate Esters on Human Health. Environmental Science & Technology, 57(4), 1764-1775. https://doi.org/10.1021/acs.est.2c04576
Vancouver
Wang X, Zhao X, Shi D, Dong Z, Zhang X, Liang W, et al. Integrating Physiologically Based Pharmacokinetic Modeling-Based Forward Dosimetry and in Vitro Bioassays to Improve the Risk Assessment of Organophosphate Esters on Human Health. Environmental Science & Technology. 2023;57(4):1764-1775. doi:10.1021/acs.est.2c04576
BibTeX
@article{Wang2023,
author = {Wang, Xiaolei and Zhao, Xiaoli and Shi, Di and Dong, Zhaomin and Zhang, Xiao and Liang, Weigang and Liu, Lingling and Wang, Xia and Wu, Fengchang},
title = {Integrating Physiologically Based Pharmacokinetic Modeling-Based Forward Dosimetry and in Vitro Bioassays to Improve the Risk Assessment of Organophosphate Esters on Human Health},
journal = {Environmental Science & Technology},
year = {2023},
volume = {57},
number = {4},
pages = {1764--1775},
doi = {10.1021/acs.est.2c04576}
}
EUVIMED